hypogonadism%20in%20males%20-%20late-onset
HYPOGONADISM IN MALES - LATE-ONSET
Late onset hypogonadism is defined as clinical and biochemical syndrome characterized by older age, set of typical symptoms, and deficiency in serum testosterone levels.
The quality of life may be decreased and multiple organ systems may be adversely affected.
Prior to the start of testosterone substitution, there should be confirmation of low serum testosterone and a confirmation of need based on clinical findings.
Only if the potential benefit exceeds the risk, then replacement testosterone should be started.

Introduction

  • A type of hypogonadism that has normal pubertal development thus w/ developed normal male secondary sex characteristics
  • Prevalence of hypogonadism increases w/ age
  • Quality of life may be decreased
  • Multiple organ systems may be adversely affected

Definition

  • Late-onset hypogonadism (LOH) is defined as a clinical & biochemical syndrome caused by androgen deficiency characterized by:
    • Older age
    • Set of typical symptoms
    • Deficiency in serum testosterone levels

Signs and Symptoms

  • Decreased sexual desire & erectile quality & frequency; especially nocturnal erections
  • Mood changes, including:
    • Decreases in intellectual activity, cognitive function, spatial orientation ability
    • Fatigue
    • Depression
    • Irritability 
  • Sleep disturbances
  • Decrease in lean body mass w/ decrease in muscle volume & strength
  • Increase in visceral fat
  • Decrease in body hair & skin alterations
  • Osteopenia, osteoporosis & increased risk of bone fractures may develop from a decrease in bone mineral density
  • Hot flushes
Editor's Recommendations
Most Read Articles
6 days ago
Older women with longer endogenous oestrogen exposure and hormone therapy use are at much higher odds of having favourable cognitive status in late life, a recent study suggests.
3 days ago
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Elvira Manzano, 4 days ago
Supplementation with omega-3 fatty acids or vitamin D3 for up to 5 years has no effect on kidney function in adults with type 2 diabetes (T2D), the VITAL-DKD* ancillary study has shown.
Jairia Dela Cruz, 2 days ago
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.